YILDIZ, R. Et Al. 2010. The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.136, no.10 , 1471-1476.

YILDIZ, R., Benekli, M., Buyukberber, S., Kaya, A. O., Ozturk, B., Yaman, E., ... Berk, V.(2010). The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.136, no.10, 1471-1476.

YILDIZ, RAMAZAN Et Al. "The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer," JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.136, no.10, 1471-1476, 2010

YILDIZ, RAMAZAN Et Al. "The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.136, no.10, pp.1471-1476, 2010

YILDIZ, R. Et Al. (2010) . "The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer." JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY , vol.136, no.10, pp.1471-1476.

@article{article, author={RAMAZAN YILDIZ Et Al. }, title={The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer}, journal={JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY}, year=2010, pages={1471-1476} }